Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Luna Zaru et al.|The Lancet|2019Cited by 1.2k
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic ConsiderationsDavid Niederseer, Christian Datz, Bernhard Wernly et al.|Journal of Clinical Medicine|2021Cited by 76
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” studyMathias Jachs, Péter Ferenci, Caroline Schwarz et al.|Alimentary Pharmacology & Therapeutics|2022Cited by 73
Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver diseaseGeorg Semmler, Christian Datz, Lorenz Balcar et al.|Frontiers in Endocrinology|2023Cited by 70
Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver DiseaseSophie Gensluckner, Elmar Aigner, Bernhard Wernly et al.|Antioxidants|2024Cited by 65